Flagship Pioneering‑backed Generate:Biomedicines filed for an IPO, spotlighting its AI‑engineered candidates including an anti‑TSLP program entering Phase 3 and other antibody and CAR‑T assets. The filing underscores investor interest in AI‑driven discovery platforms that promise compressed timelines from design to clinic and allocates proceeds toward advancing late‑stage programs and scaling development infrastructure. Generate’s move will be watched as a test of appetite for platform‑led biotechs that combine programmable biology with large, late‑stage bets; partnering agreements and clinical readouts will be central to investor valuation on debut.